`
`
`
`Filed on behalf of Valencell, Inc.
`By:
`Justin B. Kimble (JKimble-IPR@bcpc-law.com)
`
`Jeffrey R. Bragalone (jbragalone@bcpc-law.com)
`
`T. William Kennedy (bkennedy@bcpc-law.com)
`
`Jonathan H. Rastegar (jrastegar@bcpc-law.com)
`
`Bragalone Conroy PC
`
`2200 Ross Ave.
`
`Suite 4500 – West
`
`Dallas, TX 75201
`
`Tel: 214.785.6670
`
`Fax: 214.786.6680
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`APPLE INC.,
`Petitioner,
`
`v.
`
`VALENCELL, INC.,
`Patent Owner.
`
`Case IPR2017-003191
`U.S. Patent No. 8,923,941
`
`
`PATENT OWNER’S RESPONSE TO APPLE’S ADDITIONAL BRIEFING
`REGARDING CLAIMS PREVIOUSLY DENIED INSTITUTION
`
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`U.S. Patent & Trademark Office
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`
`
`1 Case IPR2017-01555 has been joined with this proceeding.
`
`
`
`
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`
`
`Patent Owner Valencell, Inc. submits this responsive brief under the Board’s
`
`Order of May 23, 2018 (Paper 39) regarding previously non-instituted claims 3-5.2
`
`I.
`
`“Application-Specific Interface” in Claim 3 Is Not a Typographical Error
`and Petitioner’s Proposed Construction Is Incorrect.
`
`Three times3 the Board correctly rejected Petitioner’s argument—which
`
`underpins its entire case against claim 3—that “application-specific interface (API)”
`
`is a typographical error. Paper 10 (“DI”) at 9-12; Paper 15 (“Dec.”), passim.
`
`Petitioner’s argument is contradicted by the unwavering use of the term “specific”
`
`in the claim language, specification, and prosecution history of U.S. Patent No.
`
`8,923,941 (“the ’941 patent”). See Ex. 1001 at Abstract, 26:15-19, and 30:62-65; see
`
`also Ex. 1002 at 47-48, 55, 95, 132, and 157. Petitioner disregards this intrinsic
`
`evidence and relies only on speculation and extrinsic evidence; but it is well settled
`
`that extrinsic evidence contrary to the meaning mandated by the intrinsic record is
`
`discounted. See Phillips v. AWH Corp., 415 F.3d 1303, 1318 (Fed. Cir. 2005) (citing
`
`Key Pharms. v. Hercon Labs. Corp., 161 F.3d 709, 716 (Fed. Cir. 1998)).
`
`
`
`2 For the reasons set forth in its May 8, 2018 email to the Board, Patent Owner
`
`respectfully preserves the right to challenge this post-SAS procedure.
`
`3 The Board re-confirmed this decision in IPR2017-00321, Paper 44 at 61-62.
`
`
`
`1
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`Further, the Board rightly concluded that the context of the use of
`
`“application-specific interface (API)” in the specification of the ’941 patent
`
`demonstrates that Petitioner is wrong to conclude that the term should be read as
`
`being equivalent to an “application programming interface.” DI at 11. The
`
`specification teaches that “[t]he multiplexed data outputs 604 may be a serial data
`
`string of activity and physiological information 700 (FIG. 18) parsed out specifically
`
`such that an application-specific interface (API) can utilize the data as required for
`
`a particular application.” Ex. 1001 at 26:15-18 (emphasis added). This explicit
`
`teaching from the ’941 patent contradicts Petitioner’s argument that “application-
`
`specific interface (API)” is equivalent to an “application programming interface”
`
`and can include any “application interface that specifies how some software
`
`components should interact with each other.” Paper 2 (“Pet.”) at 14-15. Instead, this
`
`teaching further supports the Board’s rejection of Petitioner’s unsupported
`
`construction, because it shows that the “serial data output” is created to be used with
`
`a specific, not merely a generic, application.
`
`Petitioner invites the Board to err by blatantly reading the term specific out of
`
`the claimed “application-specific interface.” Petitioner demands that the Board
`
`deviate from established claim construction standards, assume that “application-
`
`specific interface (API)” contains a typographical error, and then jump directly to
`
`extrinsic evidence. Petitioner is explicit in asking the Board to read the limitation
`
`
`
`2
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`“application-specific interface” out of the claim, overlook the consistent use of the
`
`term in the ’941 patent and file history, and the contextual explanation of the term,
`
`and to instead accept Petitioner’s expert’s opinion about what the term allegedly
`
`means. See Ethicon Endo-Surgery, Inc. v. U.S. Surgical Corp., 93 F.3d 1572, 1582
`
`(Fed. Cir. 1996) (“Ethicon . . . invites us to read its … limitation out of the claim.
`
`This we cannot do.”) (emphasis added). Such a backwards analysis is precisely what
`
`the Federal Circuit rejected in Phillips. Further, even assuming an error, the Board
`
`correctly noted that it could not speculate as to whether the error is in the words of
`
`the phrase, or in the letters of the abbreviation. DI at 9-10. Given the use of the word
`
`“specific” throughout the intrinsic record, and the explanation that it is “as required
`
`for a particular application,” it is much more plausible that any error is in the
`
`abbreviation, not in the explicit words of the preceding phrase.
`
`Having failed to convince the Board to adopt its construction of “application-
`
`specific interface (API),” Petitioner suggests that additional extrinsic evidence, in
`
`the form of deposition testimony from Patent Owner’s expert Dr. Pollonini, should
`
`overcome all of the intrinsic evidence that the Board has rightly relied upon. But Dr.
`
`Pollonini never construed the term “application-specific interface (API),” nor did
`
`Dr. Pollonini agree that there is a typographical error in claim 3. And contrary to
`
`Petitioner’s argument, Dr. Pollonini confirmed the importance of the term “specific”
`
`in the phrase, saying “[i]t could be application-specific programming interface, if
`
`
`
`3
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`you want to, you know match those two….” Ex. 1069 at 128:9-11 (emphasis added).
`
`He also testified that “the serial data output allows clearly the respiration rate to be
`
`extracted, for instance, as cited in claim 3 by an application-specific interface.” Id.
`
`at 64:23-65:3 (emphasis added). Thus, the testimony on which Petitioner now hangs
`
`its hat is, at best, taken out of context. More importantly, Dr. Pollonini’s testimony
`
`is no more than the same type of extrinsic evidence that the Board has already
`
`rejected.
`
`II. Claim 3 Is Patentable Even Under Petitioner’s Incorrect Construction.
`
`
`While Petitioner’s attempt to subvert the intrinsic record and read the phrase
`
`“application-specific interface” out of the ’941 patent is legally incorrect, the prior
`
`art does not invalidate claim 3 even under that improper construction. Patent Owner
`
`has already demonstrated that Ground 1 fails at least because the proposed
`
`combination of Luo and Craw does not disclose a PPG sensor that captures signals
`
`that are processed into a serial data output from which a respiration rate can be
`
`extracted, or a serial data output created from the signals obtained by the sensors.
`
`See Paper 22 (“POR”) at 1-2 and 13-26. Similarly, Patent Owner has already shown
`
`that Ground 6 (claim 1), and therefore Ground 7 (claim 3), fail at least because
`
`neither Mault nor Al-Ali disclose a single monitoring device capable of sensing
`
`physiological information comprising both heart rate and respiration rate, a PPG
`
`sensor from which respiration rate can be extracted after processing the PPG sensor’s
`
`
`
`4
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`signals, or a serial data output of physiological and motion-related information. See
`
`id. at 2-3 and 26-37.
`
`Thus, under either construction, Petitioner fails to carry its burden to prove
`
`that claim 3 of the ’941 patent is unpatentable.
`
`III. The Board Was Justified in Declining to Speculate About an Alleged
`Issue Under Section 112 in Claims 4 and 5.
`
`As the Board has recognized, Section 112 is not proper subject matter for an
`
`inter partes review. DI at 13 (citing 35 U.S.C. § 311(b)); see also Cuozzo Speed
`
`Techs., LLC v. Lee, 136 S.Ct. 2131, 2142 (2016) (canceling a patent claim for
`
`indefiniteness under §112 in inter partes review would be impermissible
`
`“shenanigans”). Based on the arguments presented in the Petition, the Board was
`
`correct to decline to speculate about the meaning of the term “the application” in
`
`claim 4. Patent Owner submits that the Board may properly reach the same
`
`conclusion at this juncture and decline to find that claims 4 and 5 are unpatentable
`
`under the asserted grounds, given that resolution of Section 112 issues is not
`
`permitted in an IPR. See 35 U.S.C. § 311(b).
`
`III. Alternatively, the Prosecution History Demonstrates that Claims 4 and 5
`Should Depend from Claim 3.
`
`
`
`Because the Board’s Order requires Patent Owner to address the question of
`
`“what the precise typographical error is in claim 4,” Patent Owner submits this
`
`alternative argument. The prosecution history demonstrates that the dependency of
`
`
`
`5
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`claim 4 (originally filed as claim 5) was inadvertently changed during prosecution
`
`from claim 3 (originally claim 4) to claim 1. In an amendment, Patent Owner
`
`amended the claims in certain respects, represented that claim 5 was submitted as
`
`“original,” but inadvertently submitted claim 5 with the erroneous statement that it
`
`depends from claim 1 instead of claim 4. See Ex. 1002 at 175-176. The claims were
`
`then allowed. Thus, it is clear that, but for an obvious drafting error, claim 4 should
`
`depend from claim 3. Petitioner agrees. Paper 40 (“Add. Br.”) at 6.
`
`
`
`A district court can correct an obvious drafting error in a patent where the
`
`correction is not subject to reasonable debate in view of the claim language, and the
`
`specification and the prosecution history does not suggest a different interpretation.
`
`See CBT Flint Partners, LLC v. Return Path, Inc., 654 F.3d 1353, 1358 (Fed. Cir.
`
`2011) (citing Novo Industries L.P. v. Micro Molds Corp., 350 F.3d 1348, 1354 (Fed.
`
`Cir. 2003)). While Patent Owner is not aware of a Federal Circuit decision applying
`
`that reasoning to an inter partes review proceeding, there are two instances in which
`
`the PTAB has construed a claim to correct a mere typographical error. See Apple
`
`Inc. v. FastVDO LLC, IPR2016-01203, 2017 WL 6345416 at *4 (P.T.A.B. Dec. 11,
`
`2017); K/S HIMPP v. III Holdings 4, LLC, IPR2017-00782, 2017 WL 3209159, *10
`
`(P.T.A.B. July 27, 2017). Thus, the Board may construe claim 4 to correct the
`
`typographical error such that it depends from claim 3, instead of claim 1.
`
`
`
`6
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`
`
`If the Board reaches that result, it should then find that Petitioner has not met
`
`its burden to demonstrate that claims 4 or 5 are unpatentable, because Petitioner has
`
`submitted no arguments in this proceeding that those claims, as depending from
`
`claim 3, are unpatentable. Instead, Petitioner’s only contention has been that claims
`
`4 and 5 were unpatentable if “the application” in claim 4 is construed to be “an
`
`application,” and if the Board then determines that claim 4 should depend from claim
`
`1. See Pet. at 15, 29, and 59; see also Add. Br.at 7.
`
`Petitioner’s agreement that claim 4 should depend from claim 3 cannot be
`
`squared with its request that the Board instead analyze claim 4 as depending from
`
`claim 1. Petitioner cites to no case in which a party argued that a claim should
`
`properly depend from one claim, but then be construed to depend from another claim
`
`altogether. In fact, Petitioner explicitly asks the Board to depart from what Petitioner
`
`itself contends is the meaning of claim 4, as supported by the intrinsic record. The
`
`Board should reject that invitation. Instead, the Board should either (1) decline to
`
`address a Section 112 issue or (2) construe claim 4 to depend from claim 3. In either
`
`case, the Board should find that Petitioner has failed to meet its burden to
`
`demonstrate unpatentability with respect to claims 4 and 5.
`
`
`
`
`
`7
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`Dated: June 6, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Justin B. Kimble
`Attorney for Patent Owner
`Registration No. 58,5 91
`Bragalone Conroy PC
`2200 Ross Ave.
`Suite 4500 – West
`Dallas, TX 75201
`
`
`
`8
`
`
`
`
`
`Case IPR2017-00319
`U.S. Pat. No. 8,923,941
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that this document was served via electronic
`
`mail on June 6, 2018, to Petitioner via counsel, Michelle K. Holoubek, Michael D.
`
`Specht, and Mark J. Consilvio at the email addresses: mspecht-PTAB@skgf.com,
`
`holoubek-PTAB@skgf.com, mconsilvio-PTAB@skgf.com, and PTAB@skgf.com,
`
`pursuant to Petitioner’s consent in its Petition at page 71.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Justin B. Kimble
`Attorney for Patent Owner
`Registration No. 58,591
`Bragalone Conroy PC
`2200 Ross Ave.
`Suite 4500 – West
`Dallas, TX 75201
`
`9
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`